Vertex Pharmaceuticals has provided a comprehensive update on recent progress in its R&D activities in cystic fibrosis (CF): The TRAFFIC and TRANSPORT Phase III studies of lumacaftor (VX-809) in combination with Kalydeco (ivacaftor) in people with two copies of the F508del mutation are fully enrolled. Data from these studies are expected in mid-2014, and Vertex plans to submit an NDA in the U.S. and an MAA in Europe in the second half of 2014 for the combination of lumacaftor and ivacaf...